Azathioprine / Mercaptopurine
Treatment for Crohn's Disease
Typical Dosage: Azathioprine: 2-3 mg/kg daily; Mercaptopurine: 1-1.5 mg/kg daily
Effectiveness
58%
Safety Score
30%
Clinical Trials
40
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Azathioprine: 2-3 mg/kg daily; Mercaptopurine: 1-1.5 mg/kg daily
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250
Monitoring:$900
Side Effect Mgmt:$300
Total Annual:$1,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$2,636
Cost per Remission
$3,816
Azathioprine / Mercaptopurine Outcomes
for Crohn's Disease
Efficacy Outcomes
Overall Effectiveness
+58%
Response Rate
+55%
Remission Rate
+38%
Common Side Effects
Nausea/vomiting
+15%
Myelosuppression
+8%
Hepatotoxicity
+8%
Pancreatitis
+4%
Increased lymphoma risk
+0.3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Azathioprine / Mercaptopurine in Crohn's Disease
Post-Operative Crohn's Disease Outcome in Children
NCT03681652RECRUITING
100 participants
OBSERVATIONAL
Petah Tikva, Israel
Started: Feb 11, 2019
Completed Clinical Trials
7 completed trials for Azathioprine / Mercaptopurine in Crohn's Disease
Reduce Risk for Crohn's Disease Patients
NCT02852694COMPLETEDPHASE4
192 participants
INTERVENTIONAL
Paris, France
Started: Feb 28, 2017
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
NCT01564823COMPLETEDPHASE3
86 participants
INTERVENTIONAL
Badalona, Spain +21 more
Started: Jun 1, 2012
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
NCT02177071COMPLETEDPHASE4
211 participants
INTERVENTIONAL
Melbourne, Australia +26 more
Started: Oct 9, 2015
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
NCT00946946COMPLETEDPHASE3
78 participants
INTERVENTIONAL
Vienna, Austria +1 more
Started: Feb 1, 2002
Early Immunosuppressants in Crohn's Disease
NCT00546546COMPLETEDPHASE4
120 participants
INTERVENTIONAL
Amiens, France +25 more
Started: Jul 1, 2005
Cost-effectiveness of TPMT Pharmacogenetics
NCT00521950COMPLETEDNA
853 participants
INTERVENTIONAL
Nijmegen, Netherlands +2 more
Started: Sep 1, 2007
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
NCT01235689COMPLETEDPHASE3
252 participants
INTERVENTIONAL
Started: Feb 11, 2011
Showing 20 of 40 total trials